Failures to Replicate: What Recent Negative Phase 3 Trials Have Taught Us about Amyotrophic Lateral Sclerosis Clinical Research
Author:
Affiliation:
1. Barrow Neurological Institute Phoenix AZ USA
2. Massachusetts General Hospital Boston MA USA
Publisher
Wiley
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.26999
Reference18 articles.
1. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS
2. Cytokinetics.Cytokinetics Announces COURAGE‐ALS Met Criteria for Futility at Second Interim Analysis [press release]. March 31 2023 2023.
3. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
4. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
5. MT Pharma America.Mitsubishi Tanabe Pharma America Announces Update on Global Phase 3b MT‐1186‐A02 Postmarketing Study of Oral Edaravone in ALS [press release]. March 31 2024 2024.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3